Eureka AIR delivers breakthrough ideas for toughest innovation challenges, trusted by R&D personnel around the world.

Inhibition of membrane-associated viral replication

A technology of viruses and inhibitors, applied in antiviral agents, metabolic diseases, and resistance to vector-borne diseases, etc., can solve problems such as HCV infection has no effect

Inactive Publication Date: 2001-04-04
CHANCELLOR MASTERS & SCHOLARS OF THE UNVIVERSITY OF OXFORD +2
View PDF10 Cites 5 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

For example, lamivudine (the nucleoside analog 3TC) is useful in the treatment of HBV infection but has no effect on HCV infection

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Inhibition of membrane-associated viral replication
  • Inhibition of membrane-associated viral replication
  • Inhibition of membrane-associated viral replication

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0125] Presence of antiviral antiglucosidase on MDBK monolayers exposed to BVDV

[0126] Effects on plaque formation

[0127] MDBK cells (ATCC Accession No. 22 CCL F11859, BVDV free) were grown to a semi-confluent state in each well of a 24-well plate and formed a monolayer of cells. The medium used was Dulbecco's modified Eagle's medium containing 10% (v / v) horse serum. A stock solution of the NADL strain of BVDV (ATCC Accession No. NADL 534VR) was diluted to approximately 500 to 1000 plaque-forming units (pfu) per milliliter, suspended in growth medium, and cells were incubated for one hour in the presence of virus to A multiplicity of infection (moi) (plaque formation condition) of less than 1 infects approximately 10 5 cells. growth medium alone or with Figure 5 The growth medium replaces the inoculum with the amount of drug indicated on the axis (up to 1000 micrograms NBDNJ per milliliter). Three days after infection, before and after the monolayer cells were staine...

Embodiment 2

[0133] Secretion of infectious BVDV in the presence of N-butyl-DNJ and N-nonyl-DNJ

[0134] MDBK cells were grown to a semi-confluent state in each well of a 24-well plate. Cells were then infected with BVDV by incubating them at 37°C for 1 hour in the presence of approximately 500 pfu of BVDV's NADL strain suspended in growth medium. The inoculum was replaced with growth medium or growth medium containing NBDNJ and NNDNJ at the concentrations shown in Tables 2 and 3, respectively. The supernatant was taken three days later and used to infect fresh MDBK monolayers in six-well plates. Three days later, the monolayer cells were stained with 0.2% (W / V) crystal violet in ethanol before and after staining with a microscope to detect the presence of phage plaques. Stain to check viability, detect and count virus-induced plaques. Results are expressed as percentage of plaques (=100%) formed when infection was performed with plaque detection supernatant without inhibitor. In Table...

Embodiment 3

[0143] Control detection of NB-DGJ inhibition of ceramide-specific glucosyltransferase

[0144] MDBK cells in 14 C-palmitate N-butyl-deoxygalactojirimycin in the presence of growth to confluence. Cells were washed three times with PBS, scraped from culture flasks, and extracted with chloroform:methanol (2:1, v / v) overnight at 4°C. Save the initial extract and add 0.5 ml of chloroform:methanol (2:1, V / V) for extraction at room temperature for three hours. Extracts were pooled and aliquoted for scintillation counting. The sample was adjusted to 200,000 cpm, dried under nitrogen, then suspended in 10 μl of chloroform:methanol (2:1, V / V), and separated by TLC (chloroform:methanol (2:1, V / V). Radiolabeled Lipids were detected by fluorophore and the observed dose-dependent decrease in Glc-ceramide and gangliosides (data unpublished) indicated inhibition of ceramide-specific glutransferase at concentrations that had no antiviral effect .

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

A method of inhibiting the morphogenesis of a host cell membrane budding virus and the resulting infection using a compound that inhibits a host cell glucosidase or glucosyltransferase. Methods of treating lipid storage diseases using compounds that inhibit glucosyltransferases.

Description

[0001] This application claims priority from US Provisional Application Serial No. 60 / 069245, filed December 11, 1997. field of invention [0002] The present invention relates to the use of compounds that inhibit the glucosidase activity of host cells in the treatment of viral infections. The use of compounds that inhibit the activity of glucosyltransferases in infected cells is also contemplated for the treatment of lipid storage diseases. In particular, it relates to the use of 1,5-dideoxy-1,5-imino-D-glucitol and its derivatives. Background of the invention [0003] More than 40 million people worldwide are chronically infected with hepatitis C virus (HCV), and it represents one of the most serious threats to public health in developed countries (Hoofnagle et al. (1997) New England Journal of Medicine 336:347-356 ). Hepatitis C virus infection kills more than 10,000 people each year in the United States (Hepatitis C Treatment, Washington Post, November 11, 1997, A2), a...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): C07D211/46A61K31/00A61K31/445A61K45/00A61P3/06A61P31/12A61P35/00A61P43/00
CPCA61K31/00A61K31/445A61P3/06A61P31/12A61P35/00A61P43/00Y02A50/30
Inventor B·S·布隆伯格T·M·布罗克R·A·德威克A·密塔F·普拉特T·D·布特斯N·泽茨曼
Owner CHANCELLOR MASTERS & SCHOLARS OF THE UNVIVERSITY OF OXFORD
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com